• Cash Balance: Approximately $9.1 million as of June 30, 2024.

• Operating Expenses: Approximately $2.6 million for the fiscal quarter ended June 30, 2024, compared to $3.4 million for the same period in 2023, a decrease of approximately 24%.

• Net Loss: Decreased by approximately $700,000 to $2.6 million for the fiscal quarter ended June 30, 2024, from $3.3 million in the same period in 2023.

• General and Administrative Expenses: Decreased by approximately $600,000, primarily due to a $447,000 decrease in supplies related to raw materials and lab supplies.

• Professional Fees: Decreased by approximately $300,000, mainly due to reductions in consulting expenses, scientific consulting, and legal fees.

• Payroll and Related Expenses: Increased by approximately $100,000, primarily due to $300,000 in separation expenses related to employee termination.

• Warning! GuruFocus has detected 1 Warning Sign with AEMD.

Release Date: August 14, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Aethlon Medical Inc (NASDAQ:AEMD) has received full ethics approval for a clinical trial of its Hemopurifier in Australia, which is a significant step forward in its oncology research.

• The company has successfully reduced its operating expenses by approximately 24% compared to the previous year, demonstrating effective cost management.

• Aethlon Medical Inc (NASDAQ:AEMD) has a solid cash balance of approximately $9.1 million as of June 30, 2024, providing a stable financial foundation for ongoing operations.

• The Hemopurifier has shown potential in preclinical studies to reduce extracellular vesicles, which may improve therapeutic response rates to anti-PD-1 therapies.

• The company is poised to address outbreaks and pandemics with its Hemopurifier, which has demonstrated the ability to bind and remove life-threatening envelope viruses in vitro.

Negative Points

• The company's net loss for the fiscal quarter ended June 30, 2024, was approximately $2.6 million, indicating ongoing financial challenges.

• Aethlon Medical Inc (NASDAQ:AEMD) has only treated one patient in its COVID-19 trial in India, suggesting slow progress in this area.

• There is an expectation of increased expenses related to clinical trials in Australia, which may offset recent cost reductions.

• The company is still awaiting approvals from research governance offices, which could delay the start of patient enrollment in clinical trials.

• Only approximately 30% of patients respond to current anti-PD-1 therapies, highlighting the challenge of improving therapeutic outcomes with the Hemopurifier.